|
|
|
|
Vol. 302, Issue 2, 451-465, August 2002
9-Tetrahydrocannabinol-Induced Apoptosis in the
Thymus and Spleen as a Mechanism of Immunosuppression in Vitro and in
Vivo
Departments of Microbiology and Immunology (R.J.M., C.L., M.N.) and Pharmacology and Toxicology (B.R.M., P.S.N.), Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia
| |
Abstract |
|---|
|
|
|---|
9-Tetrahydrocannabinol (THC), the main
psychoactive component of marijuana has been shown to suppress the
immune response. However, the exact mechanism of THC-induced
immunosuppression remains unclear. In the current study, we tested the
hypothesis that exposure to THC leads to the induction of apoptosis in
lymphocyte populations. Splenocytes of C57BL/6 mice cultured in the
presence of 10 µM or greater concentrations of THC showed
significantly reduced proliferative response to mitogens, including
anti-CD3 monoclonal antibodies (mAbs), concanavalin A (Con A), and
lipopolysaccharide (LPS) in vitro. Thymocytes and naive and activated
splenocytes exposed to 10 µM or 20 µM THC showed significantly
increased levels of apoptosis. Treatment with CB2 antagonist inhibited
THC-induced apoptosis in thymocytes and activated splenocytes.
Administration of 10 mg/kg body weight of THC into C57BL/6 mice led to
thymic and splenic atrophy as early as 6 h after treatment. This
effect could be partially inhibited by treatment with a caspase
inhibitor in vivo. THC exposure led to reductions in the numbers of all subpopulations of splenocytes and thymocytes examined. Functional studies revealed that splenocytes from THC-treated mice had
significantly reduced proliferative response to anti-CD3 mAbs, Con A,
and LPS in vitro. Finally, thymocytes and splenocytes exposed to THC in vivo exhibited apoptosis upon in vitro culture. Together, these results
suggest that in vivo exposure to THC can lead to significant suppression of the immune response by induction of apoptosis.
| |
Introduction |
|---|
|
|
|---|
The
use of marijuana for recreational and medicinal purposes has received
increased attention in recent years. As a medicine, marijuana has been
implicated as a potent therapeutic agent alleviating such complications
as intraocular pressure in glaucoma, and cachexia, nausea, and pain in
AIDS and cancer patients. In addition to these potentially beneficial
effects, the use of marijuana, especially for recreational purposes,
has been associated with some unwanted effects such as increased
susceptibility to infections (Morahan et al., 1979
; Cabral et al.,
1986
; Specter et al., 1991
).
These observations have led to studies examining the effects of
marijuana and its derivatives on the immune response.
9-Tetrahydrocannabinol (THC) is the major
active component of marijuana. Initial studies demonstrated that THC
possesses significant immunomodulatory properties using both in vitro
and in vivo models (for review, see Berdyshev, 2000
). For example,
exposure of macrophages to THC led to decreased production of tumor
necrosis factor-
and nitric oxide in response to lipopolysaccharide
(Jeon et al., 1996
). In addition, exposure of macrophages to THC caused
an impairment of their antigen presenting capabilities (McCoy et al.,
1999
). THC and other cannabinoids also directly affect the responses of
T and B lymphocytes. Exposure to cannabinoids leads to significant reductions in the proliferative and cytolytic response of T lymphocytes and antibody production by B cells (Pross et al., 1990
; Klein et al.,
1991
; Kaminski et al., 1994
). Studies conducted in vivo have shown that
exposure to THC can lead to increased susceptibility to infections with
various pathogens including Herpes simplex and Friend
leukemia virus (Cabral et al., 1986
; Specter et al., 1991
).
The immunomodulatory effects of THC were initially believed to be
mediated primarily through the lipophilic properties of THC leading to
direct intercalation into the cell membrane. However, it was soon
realized that the activity of cannabinoids was highly stereospecific,
suggesting that the lipophilic properties were not solely responsible
for the cannabinoid's activity. This finding led to an intensive
search for specific cannabinoid receptors. In 1988, the first
cannabinoid receptor, known as CB1, was isolated from rat brain (Devane
et al., 1988
). CB1 is primarily found in brain tissue, and low
expression has been reported in cells of the immune system, small
intestine, testis, urinary bladder, and uterus (for review, see
Berdyshev, 2000
). A second cannabinoid receptor (CB2) was cloned from a
human promyelocytic cell line and was found to be primarily expressed
on immune cells (Munro et al., 1993
). Although immune cells can express
both receptors, the expression of CB2 is believed to be around 100 times higher than CB1 (Munro et al., 1993
).
It is now generally believed that at physiological concentrations, THC acts through binding of CB1 or CB2. However, the exact consequences of the interaction between THC and its ligand remain unclear. In the current study, we investigated the possibility that the interaction between THC and CB1 or CB2 on immune cells in vivo and in vitro leads to the induction of apoptosis. The data demonstrated that treatment of mice with THC led to marked decrease in the cellularity of thymus and spleen and decreased immune responsiveness to mitogens. The ability of THC to induce immunosuppression correlated with induction of apoptosis in immune cells.
| |
Materials and Methods |
|---|
|
|
|---|
Mice. Adult female (6-8 weeks of age) C57BL/6 mice were purchased from the National Institutes of Health. The mice were housed in polyethylene cages and given rodent chow and water ad libitum. Mice were housed in rooms maintaining a temperature of 74 ± 2°F and on a 12-h-light/dark cycle.
Reagents.
THC was obtained from the National Institute on
Drug Abuse (Rockville, MD) and was initially dissolved in DMSO
(Sigma-Aldrich, St. Louis, MO) to a concentration of 20 mM and stored
at
20°C. THC was further diluted with tissue culture medium for in
vitro studies and PBS for in vivo studies. The CB1 (SR141716A) and CB2 (SR144528) antagonists were obtained from Sanofi Recherche
(Montpellier, France).
In Vitro Proliferation Assay.
The spleens were harvested
from euthanized C57BL/6 mice and placed into 10 ml of RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 5% FCS, 10 mM HEPES, 1 mM
glutamine, 40 µg/ml gentamicin sulfate, and 50 µM
2-mercaptoethanol, referred to as complete medium. The spleens were
prepared into a single-cell suspension using a laboratory homogenizer,
washed twice, and adjusted to 5 × 106/ml in
complete medium. The splenocytes (5 × 105
in 100 µl/well) were cultured in 96-well flat-bottomed plates in the
presence of various concentrations of THC (0, 1, 5, 10, and 20 µM)
and either left unstimulated or stimulated with 5 µg/ml anti-CD3 mAbs
(PharMingen, San Diego, CA), 5 µg/ml LPS (Sigma-Aldrich), or 2 µg/ml Con A (Sigma-Aldrich) for 48 h. We found that the
mitogen-induced cell proliferation assay peaks at 48 h, and
therefore, this time point was used. During the final 8 h of
culture, the cells were pulsed with 2 µCi of
3H-thymidine. DNA synthesis was determined by
-scintillation counting (Dean et al., 1990
; McKallip et al., 1995
).
Analysis of THC-Induced Apoptosis in Vitro.
The spleens and
thymi were aseptically harvested from C57BL/6 mice and prepared into a
single-cell suspension, as described above. The splenocytes were
adjusted to 5 × 106/ml in complete medium
and added to 96-well plates (100 µl/well) containing various
concentrations of THC (0, 10, or 20 µM). The splenocytes were either
left unstimulated or stimulated with LPS or Con A for 16 h for
Annexin V/PI and 24 h for TUNEL assay. We used 24-h incubation to
detect apoptosis in splenocytes using the TUNEL assay because at this
time point, we can detect significant levels of apoptosis. If we wait
for 48 h, a large proportion of cells cultured with medium alone
undergo spontaneous apoptosis, thereby making the THC-induced apoptosis
difficult to detect. In some assays using the Annexin V/PI, we used a
16-h incubation to detect apoptosis because this assay is designed to
detect early apoptosis. Thymocytes (5 × 105/well) were cultured in 96-well flat-bottomed
tissue culture plates for 16, 24, or 48 h in the presence of
various concentrations of THC (0, 5, 10, and 20 µM). After the
designated time, the splenocytes and thymocytes were harvested and
analyzed for apoptosis using both the Annexin/PI and TUNEL methods
(Vermes et al., 1995
; Kamath et al., 1997
). To detect apoptosis using
the TUNEL method, the cells were washed twice with PBS and fixed with
4% p-formaldehyde for 30 min at room temperature. The cells
were next washed with PBS, permeabilized on ice for 2 min, and
incubated with FITC-dUTP and terminal deoxynucleotidyl transferase
(Roche Applied Science, Indianapolis, IN) for 1 h at 37°C and
5% CO2 (Kamath et al., 1997
). To detect
apoptosis using the AnnexinV/PI method, the cells were washed twice
with PBS and stained with AnnexinV and PI for 20 min at room
temperature (Vermes et al., 1995
). The cells were washed twice with
PBS. The levels of apoptosis in both the TUNEL and Annexin/PI assays
were determined by measuring the fluorescence of the cells by flow
cytometric analysis. Five thousand cells were analyzed per sample.
Analysis of THC-Induced Thymic and Splenic Atrophy in Vivo. C57BL/6 mice were treated i.p. with a single dose of THC (0, 1, 5, 10, 20, or 50 mg/kg in 200 µl of PBS) or the vehicle. The thymus and spleen were harvested at various time points after THC injection (4, 6, 24, or 72 h). The cells were prepared into a single-cell suspension, as described above, and the total number of viable cells was determined by trypan blue dye exclusion.
Flow Cytometric Analysis of Splenic and Thymic Subsets. Splenocytes and thymocytes from vehicle or THC-treated mice were stained with various fluorescence-conjugated mAbs and analyzed using a flow cytometer. In brief, splenocytes were preincubated with FcR Block (PharMingen) to prevent nonspecific binding and were subsequently stained with PE-conjugated anti-CD3, anti-CD4, anti-CD8, anti-CD19, and Mac-3 mAbs (PharMingen). Thymocytes were stained with PE-conjugated anti-CD8 and FITC-conjugated anti-CD4 mAbs (PharMingen). The cells were incubated for 30 min on ice and then washed twice with PBS. Negative controls consisted of cells that were stained with appropriate fluorescence-conjugated normal isotype antibodies. Five thousand cells were analyzed per sample.
Determination of Effect of in Vivo THC Exposure on in Vitro
Splenocyte Proliferation.
C57BL/6 mice were treated with a single
dose of THC (10 mg/kg in 200 µl of PBS), and 6 h later, the
spleen cells were harvested. The spleen was prepared into a single-cell
suspension, as described above, and adjusted to 5 × 106 cells/ml in complete medium. The cells (100 µl/well) were cultured in 96-well flat-bottomed plates and either
left unstimulated or stimulated with 5 µg/ml anti-CD3, 5 µg/ml LPS,
or 2 µg/ml Con A for 48 h. The cells were cultured with 2 µCi
of 3H-thymidine for the final 8 h, and DNA
synthesis was determined by
-scintillation counting.
Analysis of THC-Induced Apoptosis in Vivo. C57BL/6 mice were treated with a single dose of THC (10 mg/kg, i.p. in 200 µl of PBS). At various time points after THC treatment, the mice were sacrificed and the thymus and spleen were harvested. The organs were prepared into a single-cell suspension, as described above. The cells were suspended at 5 × 106 cells/ml in complete medium and analyzed for apoptosis directly or after in vitro culture in 96-well flat-bottomed plates (1 × 106 cells/well in 0.2 ml of medium) for 24 h at 37°C. The cells were harvested and washed twice in PBS, and apoptosis was determined using the TUNEL method described above. In studies examining the effect of caspase inhibitors on splenic and thymic cellularity, the mice were injected with 40 mg/kg Z-VAD-FMK (R & D Systems, Minneapolis, MN) i.p. in 400 µl of PBS 1 h before treatment with THC.
RNA Isolation and RT-PCR.
RNA was isolated from 1 × 107 cells using the RNeasy Mini Kit (Qiagen,
Valencia, CA). Because CB1 and CB2 are encoded by single exons, a DNase
digestion was included in the isolation procedure to limit the
possibility of PCR amplification of CB1 and CB2 from genomic DNA. The
cDNA was prepared with the Qiagen OmniScript RT kit using 1 µg of RNA
as template for first-strand synthesis. Mouse CB2 was amplified using M
CB2 (5'-CCGGAAAAGAG GATGGCAATGAAT-3') and M CB2
(5'-CTGCTGAGCGCCCTGGAGAAC-3'), which yields a product of 479 base
pairs.
-Actin was used as a positive control [primers M BA U
(5'-AAGG CCAACCGTGAAAAGATGACC-3') and M BA L (5'-ACCGCTCGTTGCCAAT AGTGATGA-3'); product size of 427 base pairs]. PCR reactions were carried out using the following parameters: 95°C for 15 s,
58°C for 15 s, and 72°C for 30 s for 35 cycles, followed
by a final 5 min at 72°C in a GeneAmp 9700 (Applied Biosystems,
Foster City, CA). The resulting PCR products were separated on a 1%
agarose gel.
Statistical Analysis. Student's t test or Tukey-Kramer test was used to compare vehicle and THC-treated groups. p < 0.05 was considered to be statistically significant.
| |
Results |
|---|
|
|
|---|
Exposure to THC Leads to Significant Reduction in Splenocyte
Proliferation in Vitro.
Splenocytes from C57BL/6 mice were exposed
to various doses of THC (0, 1, 5, 10, and 20 µM) and either left
unstimulated or stimulated with anti-CD3 mAbs, LPS, or Con A for
48 h in vitro. The data demonstrated that exposure of splenocytes
to greater than 10 µM THC led to a significantly decreased cell
proliferative response to all mitogens tested (Fig.
1). In contrast, lower doses of THC did
not alter significantly the proliferative response. The observation
that THC exposure reduced the response to both the T-cell (Con A and
anti-CD3 mAbs) and B-cell mitogens (LPS) suggested that THC may act on
both subsets of lymphocytes.
|
THC Induces Apoptosis in Naive and Mitogen-Activated
Splenocytes in Vitro.
To test whether the THC-induced reduction in
splenocyte responsiveness to mitogens resulted from induction of
apoptosis, we determined the level of apoptotic cells in naive and
activated splenocytes. To this end, splenocytes from C57BL/6 mice were
cultured with medium alone or with mitogens, in the presence or absence of 10 or 20 µM THC for 16 (Annexin/PI) or 24 (TUNEL) h. The cells were harvested, and apoptosis was measured by Annexin/PI staining and
by using the TUNEL assay. Annexin/PI staining detects early apoptosis,
and therefore, we analyzed the cells after 16 h of THC exposure.
Using Annexin/PI staining procedure, it has been shown previously that
cells stained with Annexin V alone are indicative of early apoptotic
cells, those stained for both Annexin V and PI represent late
apoptotic/necrotic cells, and cells positive for PI alone suggest
necrotic phenotype (Vermes et al., 1995
). The data shown in Fig.
2A demonstrated that culture of
splenocytes with medium + vehicle induced significant levels of
background apoptosis. This is expected because a certain percentage of
cells when cultured in medium undergo spontaneous apoptosis, as shown previously in our studies (Kamath et al., 1997
; Camacho et al., 2001
).
Interestingly, splenocytes cultured with medium + 10 µM THC showed
significant increase in apoptosis. Furthermore, splenocytes cultured
with medium + 20 µM THC exhibited even greater levels of apoptosis.
It was interesting to note that at lower concentrations (10 µM), the
cells were predominantly Annexin V+, whereas at
higher concentrations of THC (20 µM), the cells moved to mainly
Annexin V+PI+ phenotype.
These data suggested that the Annexin
V+PI+ seen at the higher
doses of THC may represent late apoptotic cells. Together, these
results indicated that culture of splenocytes with medium + THC caused
significant increase in apoptosis when compared with cells cultured
with medium + vehicle. Similarly, when splenocytes were cultured with
mitogens such as Con A or LPS along with THC, increased percentage of
apoptotic cells were detected when compared with splenocytes incubated
with mitogens + vehicle. The induction of apoptosis by THC was
dose-related. To further corroborate the induction of apoptosis by THC,
splenocytes cultured with medium or mitogens + THC (10 µM) for
24 h were analyzed for apoptosis using TUNEL assay. The results
showed that splenocytes cultured with medium, Con A, or LPS + THC
(filled histogram) showed elevated levels of apoptosis when compared
with cell cultured with medium, Con A, or LPS + vehicle (open
histogram) (Fig. 2B). It should be noted that splenocytes cultured with
medium + THC showed higher percentages of apoptosis when compared with
cells cultured with mitogens + THC using both assays to detect
apoptosis. These data suggested that naive lymphocytes may be more
susceptible to induction of apoptosis by THC than mitogen-activated
lymphocytes.
|
-actin in various
groups, and the data were expressed as CB2/
-actin ratio (Fig
3). These results demonstrated that CB2
expression in cells cultured with medium alone was much stronger than
that seen with cells cultured with mitogens (Fig. 3). These data
suggested that CB2 expression may be down-regulated after lymphocyte
activation, which may explain why mitogen-activated lymphocytes showed
lower levels of THC-induced apoptosis than naive cells (Fig. 2).
|
Culture with CB2 Antagonist Inhibits THC-Induced Effects on
Splenocyte Proliferation and Apoptosis.
Next, we tested whether
the effects induced by THC on the proliferative response and induction
of apoptosis were mediated through CB1 and CB2. To this end,
splenocytes were cultured with various concentrations of CB1 or CB2
antagonists (SR141716A and SR144528, respectively) or the vehicle and
exposed to 10 µM THC. The splenocytes were stimulated with Con A, and
24 h later, the proliferative response and induction of apoptosis
were determined. The results showed that culturing splenocytes with 1 or 10 µM CB2 antagonist reversed the THC-induced suppression of the
proliferative response (Fig. 4A) and
induction of apoptosis (Fig. 4B). In contrast, culturing splenocytes
with CB1 antagonist had no significant effect on the THC-induced
suppression of the proliferative response (Fig. 4A) and only a slight
effect on apoptosis (Fig. 4B). Together, these data suggested that the
effects of THC on the proliferative response and induction of apoptosis
are mediated through CB2.
|
Culture of Thymocytes with THC in Vitro Triggers Apoptosis.
Next, we tested whether THC would also induce apoptosis in thymocytes.
To this end, thymocytes from C57BL/6 mice were cultured in the presence
of various concentrations of THC (1, 5, 10, and 20 µM) or the vehicle
(DMSO) for 24 and 48 h and subsequently stained for apoptosis
using the Annexin/PI (Fig. 5) and TUNEL methods (Fig. 6). The results
demonstrated that culture of thymocytes with vehicle alone for 24 h induced a significant percentage of cells to undergo apoptosis as
reported previously by us (Kamath et al., 1997
). Interestingly,
exposure of thymocytes to THC led to dose-related increase in apoptosis
as indicated by Annexin V+ cells (Fig. 5).
Similar results were seen at 48 h of culture. It should be noted
that at lower concentrations of THC, the cells were predominantly
Annexin V+ and PI
whereas
at higher doses, the cells were mainly Annexin V+
and PI+. These data were similar to that seen
with splenocytes (Fig. 2) and suggested that at higher doses of THC,
the cells were moving from apoptotic to late apoptotic/necrotic
phenotype. To corroborate these results, we also performed the TUNEL
assay, which gave similar results (Fig. 6). Together, these data
suggested that THC induces apoptosis in thymocytes.
|
|
Effects of CB1 and CB2 Antagonists on THC-Induced Apoptosis in
Thymocytes.
To investigate the role of CB1 and CB2 in THC-induced
apoptosis, thymocytes were cultured for 16 h with the vehicle or
THC and in the presence of CB1 (SR141716A) and CB2 (SR144528)
antagonists. The results showed that THC-induced apoptosis was reversed
to a significant extent by CB2 antagonist as indicated by determination of viable cells (Fig. 7A) and Annexin/PI
staining (Fig. 7B). In contrast, CB1 antagonist failed to reverse the
decrease in viable cell number (Fig. 7A) and partially reversed the
apoptosis induced by THC (Fig. 7B). It should be noted that thymocytes
cultured with CB1 or CB2 antagonists alone failed to undergo increased apoptosis when compared with vehicle controls (data not shown). Together, the data suggested that CB2 but not CB1 receptors play a key
role in THC-induced apoptosis of thymocytes.
|
Exposure to THC Results in Thymic and Splenic Atrophy in Vivo.
We carried out a series of studies to investigate whether exposure to
THC in vivo would cause decreased cellularity of the lymphoid organs.
Groups of four C57BL/6 mice were injected with various doses of THC (0, 1, 5, 10, 20 and 50 mg/kg body weight). The thymi and spleens were
harvested 24 h later. Single-cell suspensions were prepared from
these organs and enumerated by trypan blue dye exclusion. The results
demonstrated that the injection of 10 mg/kg body weight or higher doses
of THC resulted in a significant reduction in the total cellularity of
the thymus and the spleen (Fig. 8). To
determine the time kinetics of THC-induced toxicity, C57BL/6 mice were
injected i.p. with 10 mg/kg THC, and at various time points after
injection (4, 6, 24, and 72 h), the cellularity of the spleen and
thymus was determined. The data demonstrated that THC-treatment caused
a marked decrease in the cellularity of the thymus and spleen,
particularly at 6 and 24 h after THC-exposure, and that the
cellularity began recovering by 72 h (Fig. 8).
|
Effect of THC on T-Cell Subsets in the Thymus.
We next
examined whether exposure to THC (10 mg/kg for 24 h) led to
alterations in T-cell maturation in the thymus by examining the
distribution of the various T-cell subsets (Table
1). To this end, thymocytes from DMSO
(vehicle) and THC-treated mice were stained with PE-conjugated anti-CD8
and FITC-conjugated anti-CD4 mAbs, and the percentage of the four
subpopulations was examined. The results from this experiment,
summarized in Table 1, showed that THC treatment did not lead to
significant alteration in the percentage of the individual thymic
subpopulations, when compared with vehicle-treated control mice.
However, because the total thymic cellularity was decreased (Fig. 8),
the total number of individual T-cell subsets was also significantly
decreased in THC-treated mice (Table 1).
|
Effect of THC on Lymphocyte Populations in the Spleen.
We also
examined whether the reduction in splenic cellularity after THC
treatment was due to an effect on specific lymphocyte and macrophage
populations (Table 2). More specifically,
we examined whether THC treatment led to specific reduction in the
T-cell, B-cell, and macrophage populations. Splenocytes from mice
treated for 24 h with the vehicle or THC (10 mg/kg, i.p.) were
stained with fluorescence-conjugated mAbs specific for CD3 (T cell),
CD4 (T helper), CD8 (T cytotoxic), CD19 (B cell), and Mac-3
(macrophage) cell surface markers, and the percentage of the
corresponding lymphocyte populations was determined by flow cytometric
analysis. The results summarized in Table 2 showed that exposure to THC in vivo did not specifically affect any one lymphocyte population but
led to equal reduction in total cell number in each population examined.
|
In Vivo Exposure to THC Leads to Inhibition of the in Vitro
Proliferative Response of Splenocytes to Mitogens.
To
examine whether in vivo exposure to THC would alter the proliferative
response of splenocytes, mice were exposed to 10 mg/kg THC for 6 h, after which the splenocytes were harvested and stimulated in vitro
for 48 h with various polyclonal mitogens (anti-CD3 mAbs, LPS, and
Con A). The results from this experiment showed that in vivo exposure
to THC led to a significant suppression of splenocyte responsiveness to
T-cell and B-cell mitogens in vitro (Fig.
9).
|
THC Exposure Induces Apoptosis in Splenocytes and Thymocytes in
Vivo.
Next, the possibility that the observed thymic and splenic
atrophy after THC treatment was due to the induction of apoptosis was
investigated. Mice were treated with 10 mg/kg THC for various time
periods (4-72 h), the thymus and spleen were harvested and prepared
into a single-cell suspension, and apoptosis was determined using the
TUNEL method. It was observed that thymocytes and splenocytes from
THC-treated mice when analyzed directly showed no significant levels of
apoptosis when compared with the cells obtained from vehicle-treated
mice (data not shown). Previous studies from our laboratory have
demonstrated that detection of apoptosis induced by drugs or chemicals
in vivo is difficult because such cells are rapidly cleared by the
phagocytic cells (Kamath et al., 1997
). However, we have also shown
that when such cells are cultured in vitro, they exhibit increased
levels of apoptosis (Kamath et al., 1997
). In the current study,
therefore, we incubated the thymocytes from THC-injected mice in vitro
for an additional 24 h in medium and analyzed the cells for
apoptosis. The data demonstrated that thymocytes from mice injected
with 10 mg/kg THC when harvested 16 h after exposure and cultured
for an additional 24 h in vitro exhibited a significantly higher
proportion of apoptotic cells when compared with similar cells from
vehicle-treated mice (Fig. 10A). Also,
splenocytes collected from mice 6 h after THC-treatment and
cultured in vitro showed increased levels of apoptosis when compared
with the controls (Fig. 10B). Examination of splenocytes from mice
treated for more than 6 h and thymocytes from mice treated for
more than 16 h failed to show increased levels of apoptosis upon
in vitro culture (data not shown). We have shown earlier that
chemical/drug-induced apoptosis in vivo is best detected before onset
of thymic or splenic atrophy (Kamath et al., 1997
). This is because
once the atrophy in the organs begins, the apoptotic cells are rapidly
cleared by phagocytic cells and the remaining cells may represent those
that escaped apoptosis. For this reason, we used early time points such
as 6 and 16 h to study apoptosis. The decrease in spleen
cellularity was most dramatic at 6 h, and the effect on thymus was
most significant at 24 h. Therefore, the apoptosis in the thymus
was studied at 16 h. We investigated whether apoptosis in
splenocytes can be detected at time points earlier than 6 h, but
failed to observe significant levels, because of which, we used the 6-h
time point. These data together suggested that THC-induced apoptosis in
thymocytes and splenocytes is detectable only at early time points and
only after in vitro culture.
|
Treatment with Caspase Inhibitors Reduces THC-Induced Thymic
and Splenic Atrophy in Vivo and in Vitro.
To further confirm
that apoptosis was involved in the observed THC-induced thymic and
splenic atrophy, we examined the effect of pretreatment with caspase
inhibitors on the cellularity of the thymus and spleen after THC
injection. To this end, mice were injected i.p. with 40 mg/kg pan
caspase inhibitor (Z-VAD-FMK) or vehicle. One hour later, the mice were
injected with 10 mg/kg THC i.p. Six hours later, the thymic and splenic
cellularity was determined (Fig. 11).
The results showed that THC treatment led to significant reduction in
cell number in both the thymus and spleen. However, when the mice were
injected with the caspase inhibitor, the effect of THC on the thymic
and splenic cellularity was partially reversed. These data suggested
that the THC-induced decrease in thymic and splenic cellularity was
caused at least in part by activation of caspases.
|
|
| |
Discussion |
|---|
|
|
|---|
In the present study, we demonstrated for the first time that THC
can induce apoptosis in vivo in thymocytes and splenocytes. Also, we
found that THC-induced apoptosis was regulated by CB2 and was reversed,
at least in part, by caspase inhibitors. Previous studies have
suggested that THC may induce apoptosis in lymphocytes and macrophages
(Schwarz et al., 1994
; Zhu et al., 1998
). However, in these studies,
the ability of THC to induce apoptosis was studied only in vitro but
not in vivo. Zhu et al. (1998)
demonstrated that THC at 15 to 30 µM
concentrations caused an increase in apoptosis in splenocytes cultured
with Con A or peritoneal macrophages cultured with LPS. Also, THC was
shown to induce apoptosis in cultured transformed neural cells
(Galve-Roperh et al., 2000
), cortical neurons (Campbell, 2001
), human
prostate PC3 cells (Ruiz et al., 1999
), and C6 glioma cells (Sanchez et
al., 1998
). Although the mechanism by which THC triggers apoptosis is
not clear, preliminary studies have suggested the involvement of
mitochondria, cytochrome c, caspases, and Bcl-2 (Zhu et al.,
1998
; Campbell, 2001
).
The exact mechanism by which THC induces apoptosis in lymphocytes
remains unclear. It is believed that THC and other cannabinoids can act
by two distinct mechanisms. Because of its lipophilic properties, it
was thought that THC acted through direct intercalation into the cell
membrane. However, it was soon realized that the activity of
cannabinoids was highly stereospecific, suggesting that the lipophilic
properties were not solely responsible for the cannabinoid's activity.
Since then, receptors for cannabinoids were characterized. These
receptors only share 44% homology but most cannabinoids tested show
similar binding affinity to both receptors (Pertwee, 1999
). Both
receptors are coupled to G-protein, suggesting that endogenous
cannabinoids may play a role in cell signaling (Berdyshev, 2000
).
Therefore, it is possible that the observed effects of THC on the
immune response, including the induction of apoptosis, may be mediated
by signals initiated through these receptors. For example, Galve-Roperh
et al. (2000)
demonstrated that apoptosis induced by THC in C6 glioma
cells in vivo involved cannabinoid receptor-dependent pathway. In
contrast, others have shown in C6 glioma or a prostate cancer cell
model that THC-induced apoptosis was independent of the involvement of
CB1 and CB2. The present study suggests that THC-induced
immunosuppression is primarily mediated through CB2 in that culture
with the CB2 antagonist, but not the CB1 antagonist, inhibited the
effect of THC on the proliferative response and induction of apoptosis.
THC is well known for its impact on the cytokine network (Klein et al.,
2000a
). For example, the presence of THC or activation of CB1/CB2 can
block forskolin-induced accumulation of cAMP (Koh et al., 1997
; Schatz
et al., 1997
; Herring et al., 1998
), and reduced cAMP levels correlate
with the repression of IL-2 transcription and secretion (Novak et al.,
1990
). IL-2 plays an important role in the regulation of apoptosis
(Lenardo, 1991
; Deng and Podack, 1993
; Zhang et al., 1995
). Therefore,
reduction in the levels of IL-2 or other cytokines after exposure to
THC may partly account for increased apoptosis. Although this may
account for the induction of apoptosis in activated lymphocytes, in the
current study, we also noted that THC caused apoptosis in naive
lymphocytes. Thus, exposure to THC may directly trigger activation of
genes involved in apoptosis. Additional studies are clearly needed to
fully elucidate the series of events leading to increased apoptosis
both in vitro and in vivo.
Marijuana is currently used as a therapeutic agent alleviating such
complications as intraocular pressure in glaucoma, and cachexia,
nausea, and pain in AIDS and cancer patients. Many of these effects
have been attributed to the psychoactive effects of THC (Watson et al.,
2000
). In addition, the potential use of marijuana and its derivatives
in the treatment of autoimmune disorders, cancer, and neurodegenerative
diseases has received a great deal of attention in recent years (Watson
et al., 2000
). For example, as an agent in treating cancer,
cannabinoids have shown antiproliferative effects on transformed neural
(Sanchez et al., 1998
), breast (De Petrocellis et al., 1998
), and
prostate cells (Ruiz et al., 1999
), and in vivo treatment of glioma in
a rat model more recently resulted in a significant increase in
survival (Galve-Roperh et al., 2000
). Studies also suggest that
cannabinoids may constitute a powerful tool in treating autoimmune
disorders. For example, cannabidiol has been shown to alleviate
collagen-induced arthritis (Malfait et al., 2000
). Thus, the ability of
THC to induce apoptosis in activated T lymphocytes may offer new
avenues to treat autoimmune diseases and allograft rejection. If
agonists specific for CB2 can be shown to induce apoptosis, they may
constitute an excellent tool to deplete activated T cells in disease
states. The CB2 agonists have the advantage in that they lack
psychosomatic effects.
There is evidence to suggest that the doses of THC used in the current
study are pharmacologically relevant. In an earlier study, Chan et al.
(1996)
showed that rats injected with 50 mg/kg body weight of THC had a
serum concentration of 10 µM THC within 10 h of administration.
Also in these studies, mice were given as much as 500 mg/kg five times
a week for 2 years. Interestingly, despite such high levels, the
survival of those mice was higher than controls, suggesting that such
doses are well tolerated. In addition, THC administered to mice at 150 mg/kg for 11 days suppressed streptozotocin-induced autoimmune diabetes
in CD1 mice (Li et al., 2001
). Moreover, based on our studies,
cannabinoids offer new treatment modalities to treat autoimmune
diseases and cancer. In fact, we have demonstrated recently that
malignancies of the immune system are highly susceptible to apoptosis
induced by THC and CB2 agonists (McKallip et al., 2002
). Also in these studies, we were able to successfully cure a significant proportion of
mice bearing lymphomas. Thus, the use of higher concentrations of THC
may be pharmacologically relevant in the treatment of a wide number of
diseases involving the immune system. The experiments in which we
demonstrated that CB2 antagonist can block apoptosis induced by 10 µM
THC in vitro suggest that induction of apoptosis is receptor mediated
and may be independent of lipophilic properties of THC. In addition to
the possible use of THC and other CB2 agonist for therapeutic purposes,
there is evidence to suggest that the doses and concentrations used in
this study may be obtainable during recreational use. Azorlosa et al.
(1992)
showed that levels as high as 1 µM could be obtained in the
plasma of humans, and in a separate report, it was shown that THC can
be concentrated 15- to 20-fold in some tissues (Johansson et al.,
1989
). Therefore, it may be possible to reach levels as high as 20 µM
in some tissues after recreational use. Such levels of THC may lead to
significant suppression of the immune response leading to increased
susceptibility to opportunistic infections and cancer. In fact, it was
shown that treatment of mice with doses of 8 mg/kg significantly
suppressed the responses of mice to infection with Legionella
pneumophila (Klein et al., 2000b
). Therefore, additional studies
are necessary to examine the effects of a chronic low dose of THC on
the immune system of recreational users and to examine the potential
use as a chronic treatment in which long-term immunosuppression is desirable such as after allogeneic organ transplantation. However, determining how quickly and to what degree a single dose of THC altered
the immune response may have significant clinical relevance in treating
such complications as shock induced by bacterial enterotoxins or in the
treatment of immediate hypersensitivity reactions. These types of
immune responses occur rapidly and treatment of such clinical disorders
would require rapid down-regulation of the immune response.
In summary, the current study clearly demonstrates that exposure to THC leads to suppression of the immune response characterized by reduction in the response to polyclonal mitogens, reduced cellularity in the thymus and spleen, and increased induction of apoptosis. The demonstration that the THC-induced suppression of the immune response is directly related to the induction of apoptosis is an important step in understanding the mechanism of toxicity induced by THC and its potential medicinal use.
| |
Footnotes |
|---|
Accepted for publication April 10, 2002.
Received for publication January 22, 2002.
This work was supported in part by National Institutes of Health Grants R01-DA0114885 and R01-ES09098.
DOI: 10.1124/jpet.102.033506
Address correspondence to: Dr. Prakash Nagarkatti, Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA. E-mail pnagark{at}hsc.vcu.edu
| |
Abbreviations |
|---|
FCS, fetal calf serum;
LPS, lipopolysaccharide;
Con A, concanavalin A;
THC,
9-tetrahydrocannabinol;
mAb, monoclonal antibody;
FITC, fluorescein isothiocyanate;
PBS, phosphate-buffered saline;
PE, phosphatidylethanolamine;
DMSO, dimethyl
sulfoxide;
TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end
labeling;
IL-2, interleukin 2;
SR141716A, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-di-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide
hydrochloride;
SR144528, 1-[2-(naphth-2-yl)ethy]-4-(3-trifluoromethyl
phenyl)-1,2,5,6-tetrahydropyridine hydrochloride.
| |
References |
|---|
|
|
|---|
9-tetrahydrocannabinol content and number of puffs.
J Pharmacol Exp Ther
261:
114-122
9-tetrahydrocannabinol on herpes simplex virus type 2 vaginal infection in the guinea pig.
Proc Soc Exp Biol Med
182:
181-186[CrossRef][Medline].
9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice.
Fundam Appl Toxicol
30:
109-117[CrossRef][Medline].
B elements by cannabinol, a minimally CNS-active cannabinoid.
Biochem Pharmacol
55:
1013-1023[CrossRef][Medline].
9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-
B/Rel activation.
Mol Pharmacol
50:
334-341[Abstract].
9-Tetrahydrocannabinol treatment suppresses immunity and early IFN-
, IL-12 and IL-12 receptor
2 responses to Legionella pneumophila infection.
J Immunol
164:
6461-6466
9-tetrahydrocannabinol (
9-THC): a putative mechanism of cannabinoid-induced immune modulation.
Biochem Pharmacol
53:
1477-1484[CrossRef][Medline].
T lymphocytes for apoptosis.
Nature (Lond)
353:
858-861[CrossRef][Medline].
9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes.
Int Immunopharmacol
1:
699-712[CrossRef][Medline].
9-tetrahydrocannabinol).
Int J Immunopharmacol
12:
539-544[CrossRef][Medline].
9-Tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism.
FEBS Lett
458:
400-404[CrossRef][Medline].
9-Tetrahydrocannabinol induces apoptosis in C6 glioma cells.
FEBS Lett
436:
6-10[CrossRef][Medline].
9-Tetrahydrocannabinol augments murine retroviral induced immunosuppression and infection.
Int J Immunopharmacol
13:
411-417[CrossRef][Medline].
1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion.
J Exp Med
182:
699-709
9-Tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1.
J Pharmacol Exp Ther
286:
1103-1109This article has been cited by other articles:
![]() |
V. L. Hegde, S. Hegde, B. F. Cravatt, L. J. Hofseth, M. Nagarkatti, and P. S. Nagarkatti Attenuation of Experimental Autoimmune Hepatitis by Exogenous and Endogenous Cannabinoids: Involvement of Regulatory T Cells Mol. Pharmacol., July 1, 2008; 74(1): 20 - 33. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Gustafsson, B. Christensson, B. Sander, and J. Flygare Cannabinoid Receptor-Mediated Apoptosis Induced by R(+)-Methanandamide and Win55,212-2 Is Associated with Ceramide Accumulation and p38 Activation in Mantle Cell Lymphoma Mol. Pharmacol., November 1, 2006; 70(5): 1612 - 1620. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Jia, V. L. Hegde, N. P. Singh, D. Sisco, S. Grant, M. Nagarkatti, and P. S. Nagarkatti {Delta}9-Tetrahydrocannabinol-Induced Apoptosis in Jurkat Leukemia T Cells Is Regulated by Translocation of Bad to Mitochondria Mol. Cancer Res., August 1, 2006; 4(8): 549 - 562. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. McKallip, M. Nagarkatti, and P. S. Nagarkatti {Delta}-9-Tetrahydrocannabinol Enhances Breast Cancer Growth and Metastasis by Suppression of the Antitumor Immune Response J. Immunol., March 15, 2005; 174(6): 3281 - 3289. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Do, R. J. McKallip, M. Nagarkatti, and P. S. Nagarkatti Activation through Cannabinoid Receptors 1 and 2 on Dendritic Cells Triggers NF-{kappa}B-Dependent Apoptosis: Novel Role for Endogenous and Exogenous Cannabinoids in Immunoregulation J. Immunol., August 15, 2004; 173(4): 2373 - 2382. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hart, O. M. Fischer, and A. Ullrich Cannabinoids Induce Cancer Cell Proliferation via Tumor Necrosis Factor {alpha}-Converting Enzyme (TACE/ADAM17)-Mediated Transactivation of the Epidermal Growth Factor Receptor Cancer Res., March 15, 2004; 64(6): 1943 - 1950. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Friedman, C. Newton, and T. W. Klein Microbial Infections, Immunomodulation, and Drugs of Abuse Clin. Microbiol. Rev., April 1, 2003; 16(2): 209 - 219. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||